Cellectis Stock
Cellectis S.A.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- CEO
- Andre Choulika
- Employees
- 229
- Market cap
- $105 M
- IPO
- 24/03/2015
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided…
Cellectis stock: price history
1D
-6.3%
1W
-17.5%
1M
-24.6%
6M
-76.5%
YTD
-78.5%
1Y
-77.0%
2Y
-45.3%
5Y
-90.4%
10Y
-94.7%
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~114% stronger price swings than usual
Ask the agents about Cellectis
Analyst assessment of Cellectis
PRICE TARGET LOW
US$1.30
CONSENSUS
US$2.15
MEDIAN
US$2.15
PRICE TARGET HIGH
US$3.00
0
STRONG BUY
12
BUY
3
HOLD
2
SELL
0
STRONG SELL
17
TOTAL · Buy
As of: 16/09/2026
Cellectis stock metrics
P/E
-1.78
P/B
2.85
EV/EBITDA
-3.05
RETURN ON EQUITY
-53.1%
NET MARGIN
-417.3%
DEBT/EQUITY
2.06
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
85.3%
FLOAT SHARES
85,922,748
AVG. DAILY VOLUME (30D)
166,834
Institutional holders
Comparable stocks
Frequently asked questions about Cellectis stock
What does Cellectis do?
Cellectis S.A. is a company in the Healthcare sector, Biotechnology industry, headquartered in France.
The CEO is Andre Choulika, the company employs around 229 people.
The IPO was on 24/03/2015; the stock trades on NASDAQ under the ticker CLLS.
What do analysts say about Cellectis stock?
17 analysts rate the stock, the consensus is Buy (as of 16/09/2026).
The average price target is US$2.15, ranging from US$1.30 to US$3.00, with a median of US$2.15.
This is an external assessment, not a statement by Market Jury.
When does Cellectis report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly 114% stronger than usual.
Does Cellectis pay a dividend?
No, Cellectis currently does not pay a dividend.
Which stocks are comparable to Cellectis?
Comparable stocks include Nanobiotix, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Cellectis stock analyzed?
Clicking "Analyze stock" lets five strategies assess Cellectis against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.